Latest Breaking News On - Included herein - Page 1 : comparemela.com

VANCOUVER, BC, June 15, 2022 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production of the Company's ovarian cancer vaccine. BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used by BioVaxys' Lyon-based manufacturing partner, BioElpida ("BioElpida"), to validate the tumor collection protocol, cryopackaging, cryopreservation, and

United statesUnited kingdomBritish columbiaDavid berdDavin shinedlingKenneth kovanBiovaxys technology corpJba incBiovaxys coBiovaxys or companyPrnewswire biovaxys technology corpDeaconess research instituteVaxys technologyHospices civils de lyonGood manufacturing processBiovaxy lyon based